Ipamorelin Research: Selectivity Data, Bone Studies & the Phase 3 Ileus Trials
A study-by-study look at Ipamorelin — the selectivity data that made it notable, the bone and body-composition models, and the phase 3 trials that did not meet their endpoint.
Mechanism of action
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor targeted by ghrelin.
Its defining property is selectivity. Earlier secretagogues such as GHRP-6 and hexarelin also raised cortisol, prolactin and ACTH. In the original characterisation, ipamorelin released growth hormone with no significant elevation of those hormones at effective doses.
Unlike GHRH analogues such as CJC-1295, which amplify the pituitary's own GHRH signal, ipamorelin acts through the ghrelin pathway and additionally suppresses somatostatin — the brake on GH release. This is the pharmacological rationale for studying the two classes together.
Ipamorelin has minimal appetite stimulation relative to ghrelin itself, which is why it was pursued as a GH secretagogue rather than an orexigenic agent.
The studies
Ipamorelin has genuine peer-reviewed pharmacology and reached phase 3 in a clinical indication — where it failed. Both halves of that record matter.
Raun et al. — original characterisation and selectivity
To characterise ipamorelin as a novel growth hormone secretagogue and compare its hormonal selectivity against GHRP-6 and related compounds.
In vitro pituitary cell assays and in vivo swine and rodent models · hormone panel profiling
- Potent
- GH release
- No significant rise
- ACTH and cortisol
- No significant rise
- Prolactin
comparable to GHRP-6
unlike GHRP-6
- This paper is the reason ipamorelin is described as the most selective of the GH secretagogues.
- Selectivity was dose-dependent — the clean hormonal profile held at GH-effective doses, not at every dose tested.
- The comparison was against GHRP-6 and hexarelin; it says nothing about comparative efficacy versus GHRH analogues.
Bone mineral content and body-composition models
To assess the effect of chronic ipamorelin administration on longitudinal bone growth, bone mineral content and lean body mass in growing and hypophysectomised animal models.
Rodent models · chronic dosing · DEXA and bone morphometry endpoints
- Increased
- Bone mineral content
- Increased
- Longitudinal bone growth
- Increased
- Lean body mass
vs controls
- Effects were consistent with sustained GH/IGF-1 axis activation rather than a direct action on bone.
- Findings come from growing and GH-deficient animal models, where the axis has the most room to respond.
- No equivalent controlled human body-composition trial has been published.
Phase 3 postoperative ileus programme
To determine whether ipamorelin accelerates recovery of gastrointestinal function after partial bowel resection, using its prokinetic ghrelin-receptor activity.
Adults undergoing bowel resection · randomised, double-blind, placebo-controlled multicentre trials
- Not met
- Primary endpoint
- Acceptable
- Safety profile
- Discontinued
- Development
time to GI recovery
no new safety signal
for this indication
- This is the largest controlled human exposure to ipamorelin and it produced a negative efficacy result for its tested indication.
- The trials do provide useful human safety and tolerability data at clinical doses, which the preclinical work cannot.
- A failed prokinetic endpoint says nothing directly about the GH axis — but it is the honest limit of ipamorelin's clinical record.
Storage & handling
Ipamorelin research material is supplied as a lyophilised powder. Store sealed vials frozen or refrigerated, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved — do not shake.
Keep reconstituted solution at 2-8 °C and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.